What is Zacks Research’s Forecast for ESLA FY2028 Earnings?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Research analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Estrella Immunopharma in a report issued on Tuesday, July 14th. Zacks Research analyst D. Bautz expects that the company will post earnings of ($0.31) per share for the year. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.29) per share.

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Up 13.2%

ESLA stock opened at $0.84 on Thursday. The company has a market capitalization of $36.15 million, a price-to-earnings ratio of -2.47 and a beta of 0.85. Estrella Immunopharma has a 12 month low of $0.73 and a 12 month high of $3.15. The firm has a 50 day moving average of $1.04 and a two-hundred day moving average of $1.20.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Saturday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after acquiring an additional 8,318 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Estrella Immunopharma by 1,045.7% during the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after purchasing an additional 111,779 shares during the last quarter. State Street Corp grew its holdings in Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Estrella Immunopharma in the fourth quarter valued at approximately $88,000. Finally, Quadrature Capital Ltd bought a new position in shares of Estrella Immunopharma in the fourth quarter valued at approximately $43,000. Institutional investors and hedge funds own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.